Search Results - "Mooradian, M.J."

100P SPOTLIGHT real-world study: Patient characteristics and treatment patterns in patients with unresectable stage III NSCLC receiving durvalumab after chemoradiotherapy (CRT) by Mooradian, M.J., Allen, A., Cai, L., Xiao, Y., Chander, P.

Get full text

PCN44 Cost-Effectiveness of Durvalumab Following Chemoradiotherapy in Unresectable Stage III NSCLC Patients in the US: An Update Based on 4-Year Survival Data by Seal, B., Mooradian, M.J., Van Keep, M., Dunlop, W., Brannman, L., Yong, C.

Get full text

The positive effect of immune checkpoint inhibitor-induced thyroiditis on overall survival accounting for immortal time bias: a retrospective cohort study of 6596 patients by Street, S., Chute, D., Strohbehn, I., Zhao, S., Rengarajan, M., Faje, A., Seethapathy, H., Lee, M., Seethapathy, R., Drobni, Z., Rahma, O., Neilan, T.G., Sullivan, R.J., Villani, A.C., Zubiri, L., Mooradian, M.J., Reynolds, K.L., Sise, M.E.

Get full text

Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study by Dimitriou, F., Namikawa, K., Reijers, I.L.M., Buchbinder, E.I., Soon, J.A., Zaremba, A., Teterycz, P., Mooradian, M.J., Armstrong, E., Nakamura, Y., Vitale, M.G., Tran, L.E., Bai, X., Allayous, C., Provent-Roy, S., Indini, A., Bhave, P., Farid, M., Kähler, K.C., Mehmi, I., Atkinson, V., Klein, O., Stonesifer, C.J., Zaman, F., Haydon, A., Carvajal, R.D., Hamid, O., Dummer, R., Hauschild, A., Carlino, M.S., Mandala, M., Robert, C., Lebbe, C., Guo, J., Johnson, D.B., Ascierto, P.A., Shoushtari, A.N., Sullivan, R.J., Cybulska-Stopa, B., Rutkowski, P., Zimmer, L., Sandhu, S., Blank, C.U., Lo, S.N., Menzies, A.M., Long, G.V.

“…BACKGROUNDMucosal melanoma (MM) is a rare melanoma subtype with distinct biology and poor prognosis. Data on the efficacy of immune checkpoint inhibitors…”
Get full text

Clinical outcomes for EGFR-mutant adenocarcinomas (AC) that transform to small cell lung cancer (SCLC) by Marcoux, N., Piotrowska, Z., Farago, A.F., Hata, A.N., Mooradian, M.J., Drapkin, B.J., Muzikansky, A., Gettinger, S.N., Mino-Kenudson, M., Sequist, L.

Get full text

Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum by Ameri, A.H., Mooradian, M.J., Emerick, K.S., Park, J.C., Wirth, L.J., Asgari, M.M., Tsao, H., Lawrence, D., Sullivan, R.J., Demehri, S.

Get full text

133P Phase I/II study of XTX101: A masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors by Davar, D., Knecht, J.G., Vandross, A.L., Perez, C.A., Miller, D.M., Powderly, J., Bessudo, A., Montazeri, K., Mooradian, M.J., Gupta, A., Patel, E., Fantini, D., Paramasivan, S., Crowe, D., Duncan, M., Uptain, S., Luptakova, K., Sullivan, R.

Get full text